ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kyowa Kirin Co.,Ltd.
  3. Financials
  4. Total liabilities

Kyowa Kirin Co.,Ltd. (4151)

Market cap
¥1.26T
P/E ratio
16.7x
Kyowa Kirin manufactures and sells prescription pharmaceuticals through integrated operations from drug development to sales, serving healthcare markets globally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal liabilities (Million JPY)YoY (%)
Dec 31, 2025214,528-0.93%
Dec 31, 2024216,551+14.26%
Dec 31, 2023189,524+7.04%
Dec 31, 2022177,055-4.14%
Dec 31, 2021184,710+79.51%
Dec 31, 2020102,894-3.12%
Dec 31, 2019106,204+14.99%
Dec 31, 201892,362+67.04%
Dec 31, 201755,293-42.66%
Dec 31, 201696,422-8.96%
Dec 31, 2015105,906-6.91%
Dec 31, 2014113,766

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat